Pain

Data also suggests the nonionic block polymer surfactant may be harmful for children <16 years of age.

A new study suggests prescriptions for opioid use disorder did not affect current patient treatment, but new OUD patients experienced lower rates of prescription throughout 2020.

Dr. Nigel Bunnett talks about future plans to test a new IBD treatment.

If approved, the treatment would be indicated for patients with acute pain who require an opioid.

The age-adjusted rate of overdose deaths involving cocaine was 4.9 per 100,000 individuals in 2019.

New data show reduced risk of mortality, and clinical savings upward of $100,000, are linked to sometimes inaccessible substance use disorder therapies.

The label expansion is for patients aged 6 years and older.

In recent years there has been a larger rise in overdose deaths in urban counties as opposed to rural counties.

Management of the painkiller addiction crisis looked optimistic headed into 2020. The pandemic brought a heavy toll to efforts that took years to establish.

In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.

The authors of a research letter say a small minority of patients with diabetes have facial pain that cannot otherwise be easily explained.

The injection bags will be available in 1000 mg in 100 mL doses, as well as in 500 mg in 50 mL doses.

Only Nebraska and Vermont saw a decrease in NAS rates between 2010-2017.

The current literature points to the potential efficacy and safety of the anti-depressant drug, but more research is needed to verify its role in managing pain caused by vaso-occlusive crises.

Dr. Rakesh Jetly is leading a new phase 2 study testing psychedelics in veterans with PTSD.

Adolescent delinquency and perceived classmate drug use were linked to adolescent opioid misuse.

In nearly 1.9 million doses of the COVID-19 vaccine there has been only 21 total cases of anaphylaxis.

The 5 companies issued letters will have 15 days to submit a compliance plan.

Dr. Tobias Moeller-Bertram discusses how alternative therapies could replace opioids in the future for chronic pain.

An interview with a pain specialist on advancing alternative pain therapy options.

Adamis plans to address agency concerns regarding the naloxone injection application.

There was a substantial increase in drug use-related endogenous endophthalmitis hospitalizations between 2003 and 2016.

A new study finds patients with sickle cell disease are moderately adherent to hydroxyurea.

NASH and NAFLD are notoriously difficult to treat conditions.

Paul Christo, MD, discusses opioid addiction during the pandemic, the role of the clinician, and offers a hopeful outlook for the future.